UPCC 06124 CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (CAMBRIA-2)

Study of Investigational Medication for Hormone Receptor-Positive Early Breast Cancer

Enrolling By Invitation
18 years - 130 years
All
Phase 3
5500 participants needed
1 Location

Brief description of study

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Detailed description of study

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm of the study is 7 years. Eligible patients must have intermediate-high or high risk of recurrence as defined by specified clinical and biologic criteria. Concurrent use of abemaciclib is permitted in both arms. The primary endpoint of the study is Invasive breast cancer-free survival (IBCFS) and main secondary endpoints include Invasive disease-free survival (IDFS), Distant relapse-free survival (DRFS), Overall survival (OS), Safety and Clinical Outcome Assessments (COAs).

Patients will be followed for 10 years from randomization of the last patient.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer, Early Breast Cancer
  • Age: 18 years - 130 years
  • Gender: All

Inclusion Criteria:

  • Women and Men; ≥18 years at the time of screening (or per national guidelines)
  • Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with absence of any evidence of metastatic disease as defined in the protocol.
  • Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy.
  • Patients must be randomised within 12 months of definitive breast surgery.
  • Patients may have received up to 12 weeks of endocrine therapy prior to randomisation.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
  • Adequate organ and bone marrow function

Exclusion Criteria:

  • Inoperable locally advanced or metastatic breast cancer
  • Pathological complete response following treatment with neoadjuvant therapy
  • History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered a very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation
  • Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance "
  • Known LVEF <50% with heart failure NYHA Grade ≥2.
  • Mean resting QTcF interval > 480 ms at screening
  • Concurrent exogenous reproductive hormone therapy or non topical hormonal therapy for non-cancer-related conditions
  • Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors ( eg, denosumab)
  • Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant
  • Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding.
  • Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists that would preclude the patient from receiving any LHRH agonist.

The purpose of this study is to investigate the effectiveness and safety of an investigational medication compared to standard endocrine therapy for patients with ER+/HER2- early breast cancer. The study focuses on patients who have completed locoregional treatment, which may include surgery and radiotherapy, and are at intermediate-high or high risk of cancer returning.

Participants in this study will be randomly assigned to receive either the investigational medication or standard endocrine therapy. The study will evaluate various outcomes such as invasive breast cancer-free survival and overall survival. Participants may also receive abemaciclib, a medication used to treat certain types of breast cancer. Safety assessments and clinical outcomes will be monitored throughout the study.

  • Who can participate: Adults aged 18 and older with ER+/HER2- early-stage resected invasive breast cancer, who have completed locoregional treatment and have no evidence of metastatic disease, are eligible. Participants must be randomized within 12 months of definitive breast surgery and have adequate organ and bone marrow function.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or standard endocrine therapy. The study will assess the safety and efficacy of these treatments. Concurrent use of abemaciclib is allowed in both study arms.
  • Study timelines: The study will last 7 years.
Updated on 25 Jun 2026. Study ID: 24-0563
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator